Evidence map›Paper›PMID 34283400›Full record

ArticleMolecular neurobiology2021

Therapeutic Assay with the Non-toxic C-Terminal Fragment of Tetanus Toxin (TTC) in Transgenic Murine Models of Prion Disease.

Marina Betancor, Laura Moreno-Martínez, Óscar López-Pérez, Alicia Otero, Adelaida Hernaiz, Tomás Barrio, Juan José Badiola, Rosario Osta, Rosa Bolea, Inmaculada Martín-Burriel

Open access · hybridAbstract read
In one paragraph

Article in Molecular neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Recent development of oral vaccines (Review).Experimental and therapeutic medicine · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Marina BetancorCentro de Encefalopatías Y Enfermedades Transmisibles Emergentes, Universidad de Zaragoza, IA2, IIS Aragón, 50013, Zaragoza, Spain.
Laura Moreno-MartínezLaboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Aragón), AgriFood Institute of Aragon (IA2), University of Zaragoza, Miguel Servet 177, 50013, Zaragoza, Spain.
Óscar López-PérezCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto Carlos III, Madrid, Spain.
Alicia OteroCentro de Encefalopatías Y Enfermedades Transmisibles Emergentes, Universidad de Zaragoza, IA2, IIS Aragón, 50013, Zaragoza, Spain.
Adelaida HernaizCentro de Encefalopatías Y Enfermedades Transmisibles Emergentes, Universidad de Zaragoza, IA2, IIS Aragón, 50013, Zaragoza, Spain.
Tomás BarrioUMR Institut National de La Recherche Pour L'Agriculture, L'Alimentation Et L'Environment (INRAE)/École Nationale Vétérinaire de Toulouse (ENVT) 1225 IHAP (Interactions Hôtes-Agents Pathogènes), 31076, Toulouse, France.
Juan José BadiolaCentro de Encefalopatías Y Enfermedades Transmisibles Emergentes, Universidad de Zaragoza, IA2, IIS Aragón, 50013, Zaragoza, Spain.
Rosario Osta *Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Aragón), AgriFood Institute of Aragon (IA2), University of Zaragoza, Miguel Servet 177, 50013, Zaragoza, Spain.
Rosa Bolea *Centro de Encefalopatías Y Enfermedades Transmisibles Emergentes, Universidad de Zaragoza, IA2, IIS Aragón, 50013, Zaragoza, Spain. rbolea@unizar.es.ORCID http://orcid.org/0000-0002-2746-3932
Inmaculada Martín-Burriel *Centro de Encefalopatías Y Enfermedades Transmisibles Emergentes, Universidad de Zaragoza, IA2, IIS Aragón, 50013, Zaragoza, Spain.
Universidad de Zaragoza · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESÉcole Nationale Vétérinaire de Toulouse · FR

Funding

European Regional Development Fund POCTEFA 2014-2020
6 · The paper itself

Abstract

The non-toxic C-terminal fragment of the tetanus toxin (TTC) has been described as a neuroprotective molecule since it binds to Trk receptors and activates Trk-dependent signaling, activating neuronal survival pathways and inhibiting apoptosis. Previous in vivo studies have demonstrated the ability of this molecule to increase mice survival, inhibit apoptosis and regulate autophagy in murine models of neurodegenerative diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy. Prion diseases are fatal neurodegenerative disorders in which the main pathogenic event is the conversion of the cellular prion protein (PrP

Indexed as

Disease Models, AnimalAnimalsBrainFemaleMaleMiceMice, Inbred C57BLMice, TransgenicPilot ProjectsPrion DiseasesSheepTetanus ToxinTetanus ToxinAutophagyNeurodegenerationPrionPrion diseasesTetanus toxin

Identifiers

PMID34283400
PMCPMC8497292
OpenAlexW3186055983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.